Results 311 to 320 of about 5,867,860 (378)

Special Issue "Immunomodulatory Molecules in Cancer". [PDF]

Int J Mol Sci
Pantouris G.
europepmc   +1 more source

Single‐Cell RNA Sequencing and Bulk RNA Sequencing Revealed the Interplay Between Intratumoral Heterogeneity and the Tumor Microenvironment in Breast Cancer

Cancer Medicine, Volume 15, Issue 2, February 2026.
The figure shows single‐cell datasets of breast cancer collected from the GEO database, including estrogen receptor‐positive breast cancer, HER2‐positive breast cancer, and triple‐negative breast cancer. These datasets are used to analyze differences among breast cancer subtypes by studying the interactions among epithelial cells, fibroblasts ...
Yunlong Zhao, Xiaoyu Zhang, Yingying Wang, Xiaomin Yu, Fengchun Lv, Mingyu Gong, Xiu‐An Yang   +6 more
wiley   +1 more source

The Role of Therapeutic Plasma Exchange in the Management of Myeloma-Related Cast Nephropathy: A 10-Year Real-World Cohort Study. [PDF]

J Clin Med
Salur H, Atas U, Alhan N, Vural E, Iltar U, Yucel OK, Salim O.   +6 more
europepmc   +1 more source

Therapy‐Related Acute Myeloid Leukemia Following Plasma Cell Leukemia: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT With the improvement of survival in multiple myeloma (MM), therapy‐related acute myeloid leukemia (t‐AML) has emerged as a clinically relevant second primary malignancy (SPM). We report a case of MM evolving into t‐AML after multi‐agent chemotherapy and review the literature on therapy‐related leukemias in MM.
Songdi Chen, Junqing Hu, Qian Zhang, Luling Mao, Qian Jiang, Chuyun Qian, Weize Zhang, Keting Jin, Jianhu Li, Ji‐nuo Wang, Yi Zhao   +10 more
wiley   +1 more source

Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma. [PDF]

Exp Hematol Oncol
Tu C, Van der Vreken A, Meeus F, van den Broecke L, Brons J, De Veirman K, Vanderkerken K, De Bruyne E, Breckpot K, Menu E.   +9 more
europepmc   +1 more source

Minimal residual disease in solid tumors: Clinical applications and future directions

Cancer, Volume 132, Issue 3, 1 February 2026.
Abstract Minimal residual disease (MRD) refers to the presence of residual cancer cells or tumor‐derived fragments that persist after treatment and remain undetectable by conventional imaging or protein‐based assays. Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker for MRD detection.
Theresa Abdo, Ahmad Alhalabi, Sacha Yaghi, Mohammad Aloran, You Li, María Herrán, Rami Tfayli, Thomas A. Samuel, Zeina Nahleh   +8 more
wiley   +1 more source

Mechanistic Insights and Advances of Bispecific T Cell Engaging Antibodies Therapy in Multiple Myeloma. [PDF]

Medicina (Kaunas)
Tang TF, Cheong CS, Looi CY, Wong WF, Gan GG.   +4 more
europepmc   +1 more source

Vildagliptin and Omarigliptin Differentially Bind to DPP‐4 Homodimers and Modulate Osteoclast‐Mediated Bone Resorption

Comprehensive Physiology, Volume 16, Issue 1, February 2026.
Vildagliptin and omarigliptin, dipeptidyl peptidase‐4 (DPP‐4) inhibitors, have differential effects on bone cells. Although vildagliptin improved the bone microstructure of high‐fat diet‐fed rats, it was unable to downregulate osteoclastogenesis or the expression of key osteoclast transcripts.
Ratchaneevan Aeimlapa, Jiraporn Panmanee, Jarinthorn Teerapornpuntakit, Kannikar Wongdee, Jirawan Thongbunchoo, Nattapon Panupinthu, Saovaros Svasti, Nattayaporn Apaijai, Piangkwan Sa‐nguanmoo, Siriporn Chattipakorn, Nipon Chattipakorn, Narattaphol Charoenphandhu   +11 more
wiley   +1 more source

Effects of exosomes from different origins on osteoclasts. [PDF]

J Orthop Surg Res
Yuan M, Zhu T, Wang C, Xia Q, Wang Y.
europepmc   +1 more source

Single‐cell sequencing for cancer precision medicine: From mechanism discovery to diagnosis and therapeutics

Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
Single‐cell sequencing overcomes bulk sequencing limitations, enabling high‐resolution multi‐omics analysis at the single‐cell level. It reveals tumour heterogeneity, identifying key subpopulations and tumour microenvironment interactions driving progression and resistance.
Yue Zhao, Hancong Li, Huanzuo Yang, Gongshuang Zhang, Xinyue Fu, Peiheng Li, Puxing He, Shuang Wu, Han Luo   +8 more
wiley   +1 more source